Rob McKenna
About
In The Last Decade
Rob McKenna
8 papers receiving 655 citations
Hit Papers
Peers
Comparison fields: 5 of 46
- Pulmonary and Respiratory Medicine 623
- Oncology 312
- Radiology, Nuclear Medicine and Imaging 89
- Surgery 62
- Otorhinolaryngology 47
Countries citing papers authored by Rob McKenna
This map shows the geographic impact of Rob McKenna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob McKenna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob McKenna more than expected).
Fields of papers citing papers by Rob McKenna
This network shows the impact of papers produced by Rob McKenna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob McKenna. The network helps show where Rob McKenna may publish in the future.
Co-authorship network of co-authors of Rob McKenna
This figure shows the co-authorship network connecting the top 25 collaborators of Rob McKenna. A scholar is included among the top collaborators of Rob McKenna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob McKenna. Rob McKenna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | Does Sacrificial Leadership Have to Hurt? The Realities of Putting Others First | 4 |
| 3 | Washington State's 45-Year Experiment in Government Liability | 1 |
| 4 | 13 | |
| 5 | Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. breakdown → | 633 |
| 6 | Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial. | 5 |
| 7 | The presence of steroid hormone receptors in human lung cancer | 2 |
| 8 | Critical cardiopulmonary problems in the cancer patient | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.